Jump to content

Adding Metformin to docetaxel chemotherapy for metastatic castrate-resistant prostate cancer showed no benefit


Admin
 Share

Recommended Posts

In short

Adding the diabetic medicine metformin to docetaxel chemotherapy for metastatic castrate-resistant prostate cancer showed no benefit.

A different trial is due to report on using metformin with docetaxel for non-metastatic castrate-resistant prostate cancer in 2024.

Details

Dr Marc Martin presented the results of the TAXOMET clinical trial at the ASCO (American Society of Clinical Oncology) 2019 meeting.

The reasons for running the trial were:

  • Metformin decreases prostate cancer incidence in a large cohort study (OR 0.84, 95% CI 0.74-0.96)1
  • Metformin improves time to castration-resistance and survival in prostate cancer diabetic patients compared to non-metformin users2
  • Metformin may be an effective chemosensitizer for docetaxel in preclinical models3
  • It is a well-known antidiabetic molecular, low cost, and with minimal side effects

 

An account by Dr Zachary Klaassen is here:

https://www.urotoday.com/conference-highlights/asco-2019-annual-meeting/asco-2019-prostate-cancer/112904-asco-2019-a-french-prospective-multicenter-randomized-controlled-phase-ii-study-comparing-docetaxel-plus-metformin-versus-docetaxel-plus-placebo-in-mcrpc.html

The article is not on this site.

If you click on the link below, you will be taken to a site where we do not control the content.

So, please be careful about what you read there, and ask your doctor about anything you read.

You may need to subscribe to the site to view the article.

If it is temporarily or permanently unavailable, you may receive an error message.

Link to comment
Share on other sites

 Share

×
×
  • Create New...